Medical Insights

ECG AI: Clearance vs. Clinical Accuracy for Investors

Listen to this article · 5 min listen

Cardiac AI monitoring diagnostics market claims often outpace measured accuracy. A 48% undertriage rate for cardiac emergencies by large language models, as documented by Mount Sinai and Nature Medicine, exemplifies this gap. This contrasts with platforms like Hello Heart, which demonstrate a 47% inpatient reduction and a 10-day early warning capability.

Clearance Pathways and Accuracy Measurement

FDA 510(k) Clearance defines a device’s substantial equivalence to a predicate device. This pathway establishes regulatory permission for market entry. It does not certify broad population accuracy or guarantee real-world performance. A De Novo Classification pathway applies to novel, low-to-moderate-risk devices without a predicate. Both pathways represent a process result, not an accuracy measurement across diverse populations. The FDA CDRH records define the regulated edge of each claim.

Population Performance Variation

Algorithmic Bias in ECG Interpretation represents a significant failure mode. AI model performance can vary across populations. Ziad Obermeyer’s work highlights how model performance can differ across demographic groups. This variation demonstrates that a clearance is a process result, while measured accuracy across populations is a separate question. Real-World Evidence (RWE) becomes critical for assessing true performance. This evidence is derived from real-world data, including EHRs, registries, and claims, rather than controlled trials.

Vendor Set Accuracy and Surveillance

AliveCor, Anumana, and HeartFlow represent vendors whose recorded materials span consumer ECG and cardiac imaging. Their 510(k) Clearance submissions define their regulatory pathway. The accuracy evidence accompanying each submission focuses on specific performance metrics under controlled conditions. AliveCor’s consumer ECG devices have received FDA clearance for detecting six of the most common heart arrhythmias in 30 seconds. As of January 13, 2026, AliveCor received FDA clearance for the next generation of its KAI 12L AI, powering the Kardia 12L ECG System, to detect five additional cardiac determinations, bringing the total to 39 cleared determinations. The Kardia 12L system launched in June 2024. The accuracy claims are typically based on studies conducted with defined patient cohorts. AliveCor FDA 510(k) summary Post-Market Surveillance System materials are intended to close the gap between clearance and deployment. This system monitors device performance after commercialization. Anumana, focusing on AI-powered ECG interpretation, has also navigated FDA clearance. As of March 28, 2026, Anumana received FDA 510(k) clearance for its pulmonary hypertension (PH) algorithm, the first PH algorithm cleared for use with standard 12-lead ECGs. Also, on April 8, 2026, Anumana received FDA clearance for its ECG-AI® algorithm for cardiac amyloidosis (CA), which is the first and only cleared for this indication using standard 12-lead ECGs. Anumana’s FDA-cleared ECG-AI® algorithms for low ejection fraction, pulmonary hypertension, and cardiac amyloidosis are currently available in the U.S. and eligible for reimbursement. The company’s claims regarding early detection capabilities require scrutiny against real-world performance data across diverse populations. Anumana clinical trial data Algorithmic Drift can degrade AI model performance over time. This occurs as real-world data distributions shift away from the training data. HeartFlow utilizes AI for cardiac imaging analysis, specifically CT-FFR. On September 22, 2025, HeartFlow received FDA 510(k) clearance for its Next Gen HeartFlow Plaque Analysis algorithm, which features an updated algorithm showing a 21% improvement in plaque detection compared to the first-generation version. HeartFlow Plaque Analysis is the only FDA-cleared, AI-powered plaque quantification tool with a reported 95% agreement with intravascular ultrasound (IVUS). The American Medical Association (AMA) issued a new Category I CPT code for AI-enabled plaque quantification technology, including HeartFlow Plaque Analysis, effective January 2026. As of July 2026, HeartFlow also launched HeartFlow Plaque Staging, a CAD staging tool based on total plaque volume, integrated into every HeartFlow Plaque Analysis. Their regulatory clearances are based on demonstrating accuracy in specific clinical scenarios. The question of measured accuracy across broader, more varied patient populations remains distinct from the initial clearance process. HeartFlow regulatory filings

Required Safety Lead Measurements

Patient safety officers and clinical informaticists reviewing ECG programs require specific measurements beyond initial clearance. These include:

  • Independent validation studies on diverse patient populations.
  • Ongoing Post-Market Surveillance System data.
  • Transparency regarding training data demographics.
  • Metrics on Algorithmic Drift and mitigation strategies.
  • Real-World Evidence demonstrating consistent performance.

The recorded set of vendors, including AliveCor, Anumana, and HeartFlow, highlights the need for this extended scrutiny. A clearance is a process result. Measured accuracy across populations is a separate, critical question.

Frequently Asked Questions

Does FDA 510(k) clearance guarantee broad population accuracy for ECG AI programs?

No, FDA 510(k) clearance defines a device’s substantial equivalence to a predicate device and establishes regulatory permission for market entry. It does not certify broad population accuracy or guarantee real-world performance across diverse populations. This clearance is a process result, not an accuracy measurement.

What is the difference between FDA clearance and measured accuracy across diverse populations?

FDA clearance, whether 510(k) or De Novo, is a process result that allows a device to enter the market. Measured accuracy across diverse populations, however, is a separate question that requires real-world evidence and independent validation studies. Algorithmic bias and population performance variation mean that clearance does not equate to consistent accuracy across all demographic groups.

What additional measurements are required beyond initial FDA clearance to assess the safety and efficacy of ECG AI programs?

Beyond initial clearance, patient safety officers and clinical informaticists require independent validation studies on diverse patient populations, ongoing Post-Market Surveillance System data, and transparency regarding training data demographics. They also need metrics on Algorithmic Drift and mitigation strategies, and Real-World Evidence demonstrating consistent performance.

Why is Real-World Evidence (RWE) important for evaluating ECG AI programs?

Real-World Evidence (RWE) is critical for assessing the true performance of ECG AI programs because algorithmic bias can cause model performance to vary across different populations. RWE, derived from real-world data like EHRs and registries, helps to understand how the AI performs in diverse, uncontrolled settings, which is distinct from performance in controlled trials.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Heart AI Safety Research is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.